追踪神经科学确保101万美元用于发展ALS治疗,针对神经通讯蛋白。 Trace Neuroscience secures $101M to develop ALS treatment, targeting nerve communication protein.

新的生物技术公司 " Trace Neuroscience " 已经获得1.01亿美元的资金,用于开发ALS的治疗方法,ALS是一种神经退化性疾病,影响到联合王国5 000人。 Trace Neuroscience, a new biotech firm, has secured $101 million in funding to develop a treatment for ALS, a neurodegenerative disease affecting 5,000 people in the UK. 该公司旨在恢复对神经和肌肉之间沟通至关重要的UNC13A蛋白质,以延缓疾病发展速度。 The company aims to restore the UNC13A protein, essential for communication between nerves and muscles, to slow disease progression. 资金由第三岩风投公司领导, 将支持抗意义寡核酸治疗的临床开发. The funding, led by Third Rock Ventures, will support clinical development of an antisense oligonucleotide therapy.